Outcomes in vitamin K antagonist treated atrial fibrillation patients with stable international normalized ratios

被引：0
|
作者：
Bonde, A. Nissen [1 ]
Staerk, L. [1 ]
Gislason, G. [1 ]
Torp-Pedersen, C. [2 ]
Lip, G. Y. H. [3 ]
Olesen, J. B. [1 ]
机构：
[1] Gentofte Univ Hosp, Gentofte, Denmark
[2] Aalborg Univ, Aalborg, Denmark
[3] Birmingham City Hosp, Birmingham, W Midlands, England
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4016
引用
收藏
页码：838 / 839
页数：3
相关论文
共 50 条
  • [1] COST OF VISITS ASSOCIATED WITH MANAGEMENT OF INTERNATIONAL NORMALIZED RATIO (INR) RESULTS IN ATRIAL FIBRILLATION (AF) PATIENTS TREATED WITH VITAMIN K ANTAGONIST (VKA)
    Ansolabehere, X.
    Augier, G.
    VALUE IN HEALTH, 2017, 20 (05) : A362 - A362
  • [2] Atrial Fibrillation Ablation in Patients with Therapeutic International Normalized Ratios
    Schmidt, Martin
    Segerson, Nathan M.
    Marschang, Harald
    Akoum, Nazem
    Rittger, Harald
    Clifford, Sarah M.
    Brachmann, Johannes
    Daccarett, Marcos
    Marrouche, Nassir F.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2009, 32 (08): : 995 - 999
  • [3] Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation
    Darwiche, W.
    Bejan-Angoulvant, T.
    Dievart, F.
    Babuty, D.
    Angoulvant, D.
    Fauchier, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 54 - 54
  • [4] Real-Life International Normalized Ratio Profile in Patients with Non-Valvular Atrial Fibrillation Prescribed Vitamin K Antagonist
    Farag, Shereen Ibrahim
    Arafa, Osama Sanad
    Hassan, Amal Abou Elfadl
    Mashhour, Haldy Magdy
    Bendary, Ahmed Mahmoud
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2020, 16 (04) : 522 - 527
  • [5] Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonist
    Darwiche, W.
    Bejan-Angoulvant, T.
    Angoulvant, D.
    Babuty, D.
    Fauchier, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 41 - 41
  • [6] Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants
    Wu, Victor Chien-Chia
    Wang, Chun-Li
    Huang, Yu-Chang
    Tu, Hui-Tzu
    Huang, Yu-Tung
    Huang, Chien-Hao
    Chen, Shao-Wei
    Kuo, Chang-Fu
    Hung, Kuo-Chun
    Chang, Shang-Hung
    EUROPACE, 2023, 25 (05):
  • [7] Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants
    Sbrana, Francesco
    Ripoli, Andrea
    Dal Pino, Beatrice
    ACTA CARDIOLOGICA, 2022, 77 (06) : 565 - 565
  • [8] The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic
    Al-Khalili, Faris
    Lindstrom, Catrine
    Benson, Lina
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (04) : 779 - 785
  • [9] Prevalence and predictors of left atrial thrombosis in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants
    Angelini, Filippo
    Bocchino, Pier Paolo
    Peyracchia, Mattia
    Saglietto, Andrea
    Magnano, Massimo
    Patane, Nicolo
    D'Ascenzo, Fabrizio
    Giustetto, Carla
    Anselmino, Matteo
    Gaita, Fiorenzo
    Toso, Elisabetta
    ACTA CARDIOLOGICA, 2023, 78 (03) : 290 - 297
  • [10] Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation
    Sibai, Mehdi-Sylvain
    Bellarbre, Fabienne
    Ghazali, Nisrin
    Bureau, Marie-Laure
    Priner, Mathieu
    Ingrand, Pierre
    Paccalin, Marc
    GERIATRIE ET PSYCHOLOGIE NEUROPSYCHIATRIE DE VIEILLISSEMENT, 2014, 12 (01): : 20 - 24
12345